Advent HoldCo has declined to purchase Lanxess stake in the joint venture firm Envalior, a high-performance engineering materials producer, which was tendered in September 2025. Advent informed Lanxess of its decision, citing its contractually agreed financing condition. As a result, the additional tender and purchase periods for Lanxess' shares in Envalior in 2027 and 2028 will now apply, as outlined in the ad hoc announcement from September 23, 2025.

Lanxess, the German specialty chemicals company, will continue to play an active role in shaping the expected positive development of Envalior. Key drivers of this development include market recovery, synergies between the two companies, and consolidation among direct competitors.

Despite not receiving proceeds from the sale of its Envalior stake in 2026, Lanxess remains solidly financed, holding a strong cash position and undrawn, committed credit lines of over €1.35 billion. As such, the repayment of the bond maturing in October 2026 is secured, with no financial covenants attached to the financing instruments. Lanxess continues to have unrestricted access to the debt capital markets.

Reducing financial debt remains a key priority for Lanxess and will announce its financial results for 2025 on March 19, 2026.

In May 2022, Royal DSM agreed to sell its Engineering Materials business to Advent International and Lanxess for €3.85 billion. Envalior was formed in April 2023 through the merger of Lanxess High Performance Materials and DSM Engineering Materials.